To investigate the association of complete macular dryness after four loading injections of faricimab with treatment burden and dosing intervals over two years in treatment-naïve neovascular age-related macular degeneration (nAMD). This retrospective consecutive case series included treatment-naïve nAMD eyes treated with four monthly loading intravitreal injections of faricimab followed by a treat-and-extend (TAE) regimen in which treatment intervals were adjusted in 2-week increments according to disease activity. Eyes were classified according to complete absence of intraretinal and subretinal fluid after the fourth injection. The primary outcome was the cumulative number of faricimab injections during 2 years. Secondary outcomes included year-1 and year-2 injection numbers and treatment intervals. Ninety-one eyes were included. Complete macular dryness after the fourth injection (Week 16) was achieved in 73 eyes (80.2
To evaluate the 6-month efficacy and safety of toric implantable collamer lens (TICL) implantation in myopic patients with asymmetric bow-tie corneal astigmatism. This prospective cohort study included 25 eyes from 16 patients with asymmetric bow-tie astigmatism and 41 eyes from 24 patients with symmetric bow-tie astigmatism, all undergoing TICL implantation. Corneal topography was assessed using Pentacam high-resolution. Uncorrected and corrected distance visual acuities (UDVA and CDVA), refraction, and higher-order aberrations (HOAs) were evaluated preoperatively and at 1, 3, and 6 months postoperatively. Vector analysis was employed to assess astigmatic changes. Postoperatively, 100
Immune checkpoint inhibitors (ICIs) are increasingly used across a growing range of malignancies. ICI-associated orbital inflammation is a rare immune-related adverse event (irAE) that remains poorly characterised despite its potential for substantial visual morbidity. A systematic search of PubMed, Ovid MEDLINE, Embase, Scopus, and Google Scholar was performed in September 2026. Studies reporting orbital inflammatory disease during or following ICI therapy were included. Fifty-seven studies reporting 81 patients were included. The median age at presentation was 65.6 years (IQR, 55.5–77.0), and 63
To determine the incidence, predictors, and visual impact of postoperative epiretinal membrane (ERM) and cystoid macular oedema (CMO) after primary pars plana vitrectomy (PPV) for giant retinal tear–related rhegmatogenous retinal detachment (GRT-RRD). Retrospective single-centre cohort study of 110 eyes undergoing primary PPV for GRT-RRD at Manchester Royal Eye Hospital (2012–2024). Postoperative optical coherence tomography (OCT) adequate to determine ERM/CMO status was available for 90 eyes. ERM (stage 1–4) and CMO (intraretinal fluid) within the central 1 mm were graded on OCT. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were assessed preoperatively, at 2 months, and at discharge. Predictors of ERM were evaluated using univariable and multivariable logistic regression; CMO predictors were assessed using univariable analyses. Among evaluable eyes (n=90), ERM developed in 60.0
Cardiovascular events have been shown to follow seasonal and monthly distributions. It is unclear whether this applies to retinal vascular diseases. This study aims to determine the existence of seasonal variations in the onset of retinal artery occlusions (RAO) in a European population. This retrospective, monocentric study included 646 eyes of 646 patients who were treated for RAO at the University Hospital Münster, Germany, between 2014 and 2024. Data on the exact diagnosis, day of presentation, intake of anticoagulation (AC) and general patient characteristics were collected. To determine seasonal variations in the presentation of RAO Chi-Square Test for specified proportions and Poisson regression were applied. Additional subgroup analyses further distinguished between central retinal artery occlusions (CRAO) and branch retinal artery occlusions (BRAO) and assessed whether pre-existing AC or antiplatelet (AP) medication status was associated with the temporal distribution of RAO presentations. No significant seasonal variation in the occurrence of RAO was observed (χ² p = 0.11; Poisson regression p = 0.24). Monthly analysis revealed significant variation according to the chi-square test (p = 0.03), which was not confirmed by Poisson regression (p = 0.07). In the CRAO subgroup, no significant seasonal variation was observed (χ² p = 0.22; Poisson regression p = 0.22), whereas monthly variation was significant in both the chi-square analysis (p = 0.03) and Poisson regression (p = 0.01). No significant seasonal or monthly variation was observed for BRAO. Pre-existing AC/AP medication status was not significantly associated with the seasonal distribution of RAO presentations in any of the analyzed groups. This study characterizes temporal fluctuations in RAO presentations and highlights the necessity for further investigations into potential underlying pathophysiological mechanisms, in order to better understand patterns of RAO presentations and their potential clinical relevance.
